Atropine is given when the body’s “rest and digest” nervous system is working too hard, slowing the heart to dangerous levels, flooding the airways with secretions, or constricting the pupils during eye inflammation. Its most common emergency use is for symptomatic bradycardia, a dangerously slow heart rate that causes signs of poor blood flow. But the drug has several other well-defined indications, from organophosphate poisoning to eye conditions, each with its own timing and criteria.
Symptomatic Bradycardia in Adults
A slow heart rate alone is not enough to justify atropine. The trigger for treatment is a slow rate combined with symptoms of inadequate circulation: altered mental status, chest pain from reduced blood flow, signs of heart failure, low blood pressure, or shock. These symptoms indicate the heart isn’t pumping fast enough to meet the body’s needs, and that’s when atropine becomes a first-line intervention.
The American Heart Association’s current ACLS algorithm recommends a 1.0 mg initial intravenous dose for adult bradycardia. The 2023 European Society of Cardiology guidelines similarly recommend atropine as a Class I (highest level) treatment for sinus bradycardia with hemodynamic instability or high-grade heart block without a stable backup rhythm. If the first dose doesn’t improve the heart rate and symptoms, additional doses can be given, though the total amount is capped to avoid toxicity. When atropine fails, temporary pacing or other medications become necessary.
Pediatric Bradycardia
In children, the American Heart Association and the American Academy of Pediatrics recommend atropine at 0.02 mg/kg given intravenously, with a minimum single dose of 0.1 mg and a maximum single dose of 0.5 mg. It may be repeated once. The minimum dose matters because doses that are too small can paradoxically worsen bradycardia. As with adults, the child needs to show signs that the slow heart rate is causing real harm, not just a low number on the monitor.
Organophosphate and Nerve Agent Poisoning
Organophosphate poisoning, whether from pesticides, certain industrial chemicals, or nerve agents, overstimulates the body’s cholinergic system. The result is a characteristic and dangerous combination: excessive saliva and bronchial secretions, constricted airways, a dangerously slow heart rate, and profuse sweating. Atropine directly counteracts these effects by blocking the same receptors that the poison is overstimulating.
The decision to give atropine in poisoning cases hinges on three main signs: excessive saliva or airway secretions, difficulty breathing from bronchospasm, or bradycardia. Doses in poisoning are far higher than those used for simple bradycardia. Patients may receive 2 to 3 mg every 20 to 30 minutes, and total doses can climb as high as 20 mg depending on the severity. When a patient doesn’t improve, the dose is doubled every 3 to 5 minutes until respiratory secretions clear and the airways open up.
Clinicians track a set of physical signs to know when enough atropine has been given, a state called “atropinization.” The key markers are dry skin and mucous membranes, reduced bowel sounds, faster heart rate, no wheezing, and cleared secretions. Of these, the cardiorespiratory signs (heart rate, blood pressure, breathing) are more important targets than pupil size or skin dryness. In fact, pupil dilation and heart rate are considered poor indicators of adequate dosing in poisoning cases specifically because the overwhelming cholinergic load makes them unreliable early markers.
Mushroom Poisoning
Certain mushroom species in the Clitocybe and Inocybe genera contain muscarine, a compound that produces effects very similar to organophosphate poisoning: heavy salivation, tearing, sweating, nausea, and a slow heart rate. Interestingly, although the fly agaric mushroom (Amanita muscaria) is the species muscarine was named after, it typically doesn’t contain enough of the compound to cause this syndrome.
When a patient presents with cholinergic symptoms after mushroom ingestion, atropine is given at lower doses than in pesticide poisoning, typically 0.5 to 1 mg intravenously in adults or 0.01 mg/kg in children. The goal is the same: block the excess cholinergic stimulation until the body clears the toxin.
Preoperative and Procedural Use
Before certain surgeries and procedures, atropine is used to dry up excess saliva and airway secretions that could complicate anesthesia. This is especially relevant during procedures involving the airway, where pooling secretions can obstruct the view or increase aspiration risk. Atropine is also given before some procedures to prevent a reflex drop in heart rate caused by manipulation of the vagus nerve, such as during intubation or certain abdominal surgeries.
Eye Conditions
In ophthalmology, atropine eye drops serve a completely different purpose. For eye inflammation such as uveitis or iritis, atropine relaxes the muscles inside the eye, reducing pain from spasm and preventing the iris from scarring to the lens. The standard dose for adults is 1 or 2 drops of 1% atropine up to four times daily. Children receive 1 drop up to three times daily. Atropine drops are also used before certain eye examinations to widen the pupil for a better view of the retina.
When Atropine Should Not Be Given
The most well-known contraindication is narrow-angle glaucoma. Atropine dilates the pupil, and in people with a particular eye anatomy, this dilation pushes the iris forward against the drainage structures of the eye. The iris physically blocks fluid from exiting the eye, causing pressure to spike rapidly. This can cause a painful acute glaucoma attack and, if untreated, permanent vision damage. The risk applies to both systemic atropine (which can dilate the pupils as a side effect) and atropine eye drops.
Other situations where atropine is avoided include obstructive conditions of the gastrointestinal or urinary tract, where its slowing effects on smooth muscle would worsen the obstruction. In bradycardia caused by hypothermia, atropine is generally ineffective because the slow heart rate is a direct result of the cold, not excessive vagal tone. Rewarming the patient is the appropriate treatment in those cases.
In cardiac arrest rhythms like asystole and pulseless electrical activity, atropine was once part of the standard protocol but was removed from the AHA cardiac arrest algorithm in 2010 after evidence showed it didn’t improve outcomes. It remains indicated only for bradycardia with a pulse.